Sponsors and Exhibitors
Our industry sponsors are at the core of the research and development that contributes to the improvement of patient care. They provide the essential data on products and resources to enable physicians in daily practice and improve patient outcomes.
EAACI’s Hybrid congress will provide sponsors and exhibitors further unique opportunities to reach the EAACI community worldwide. The very latest developments will be presented, discussed and debated during the EAACI Hybrid Congress 2024.
For more information on the sponsor opportunities visit our EAACI Sponsor Online Platform (ESOP) by clicking here.
For further sponsor information, please visit our Industry Service Centre – click here (NB: to be able to access this specific area link on the ESOP you must have a unique user name and password)
Ensure you are at the forefront of research, and support Allergy and Immunology development by sharing Industry activities and attending the following:
Industry Symposia
Delegates are invited to attend a series of Industry Symposia included in the scientific programme of the Congress. All symposia and workshops offer relevant data on up-to-date scientific information and developments from the Industry.
Exhibition
Join us in meeting with key industry experts, exchange knowledge on critical areas of development and research in allergy and immunology.
The onsite and virtual exhibitions will be open according to the main scientific programme timetable, subject to final adjustments.
- Virtual Exhibition – open from 31 May 2024 until 30 November 2024
- Start of onsite Exhibition: 31 May 2024 – 9:00 (CET)
- End of onsite Exhibition: 2 June 2024 – 17:30 (CET)
EAACI Mobile App
Company & Product Descriptions available in the EAACI Events mobile app.
The EAACI smartphone app enables you to explore the EAACI Hybrid Congress 2024 programme and exhibition at your fingertips.
Download the EAACI Mobile App before congress through the following PDF below
EAACI would like to thank all the past and present Congress exhibitors and sponsors:
- ALK – Abelló
- Abbott Technologies
- Aimmune Therapeutics
- Allergopharma
- Allergy Therapeutics
- AstraZeneca PLC
- Astria Therapeutics
- Beckman Coulter
- BioCryst Pharmaceuticals
- Breath Purity
- Bedfont Scientific
- Blueprint Medicines
- Bristol Myers Squibb
- Bühlmann Laboratories
- Celltrion Healthcare
- C-Luminary Biotechnology
- CSL Behring
- DBV Technologies
- Diater
- Dr. Fooke-Achetrrath Laboratorien GmbH
- EUROIMMUN AG
- ExBio Prague
- FAES FARMA
- Fluidigm
- GlaxoSmithKline plc
- Hangzhou Zheda Dixun Biological Gene Engineering Co., Ltd.
- HAL Allergy
- Helmut Hund
- Hippo DX
- Hycor Biomedical
- InBio
- Ionis Pharmaceutical
- Inmunotek
- Imperial College London
- Karger Publishers
- KalVista Pharmaceuticals
- LETI Pharma
- Lofarma
- MacroArray Diagnostics
- MCG Diagnostics
- MENARINI GROUP
- MSD
- Nestle Purina PetCare
- Nestle Health Science
- Nexkin Medicial
- Noucor
- Novartis
- Minaris Medical America
- Orion Pharma
- OM Pharma
- Pain Care Labs
- Pfizer
- Pharming Group NV
- Pharm-Olam International
- Probelte Pharma
- Reacta Healthcare
- Red Maple Trials
- Phillips
- Reckitt Benckiser
- Roxall Group
- Sanofi Regeneron
- Scibase
- Smart Practice
- Stallergenes Greer
- Takeda
- Thorasys
- Thermo Fisher Scientific
- Wisepress
We are happy to assist companies in selecting the various Industry options at the EAACI Hybrid Congress 2024. Please contact us at sponsors@eaaci.org to discuss the various options available.